New ZealandTuberculosis profile
Population  2014 4.5 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.13 (0.13–0.13)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.42 (0.18–0.77) 9.4 (4–17)
Incidence  (includes HIV+TB) 0.33 (0.29–0.38) 7.4 (6.5–8.4)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.08 (0.07–0.09)
         
Case detection, all forms (%) 89 (79–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.9 (0.11–3.2) 17 (2.1–48)
MDR-TB cases among notified pulmonary
TB cases
2 (0–6) 2 (0–4)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 160   4
Pulmonary, clinically diagnosed 19   0
Extrapulmonary 111   3
       
Total new and relapse 297    
Previously treated, excluding relapses 5    
Total cases notified 302    
Among 297 new and relapse cases:
19 (6%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases      
Patients started on MDR-TB treatment ***      
TB/HIV 2014 Number (%)
TB patients with known HIV status 220 (73)
HIV-positive TB patients 2 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (84) 269
Previously treated cases, excluding relapse, registered in 2013 (80) 5
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012 (25) 4
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-06 Data: www.who.int/tb/data